Base de dados : HANSEN
Pesquisa : HANSENIASE/EPIDEMIOL [Descritor de assunto]
Referências encontradas : 1850 [refinar]
Mostrando: 1 .. 20   no formato [Detalhado]

página 1 de 93 ir para página                         

  1 / 1850 HANSEN  
              next record last record
seleciona
para imprimir
Id:27318
Autor:Anon.
Título:Current literature.
Fonte:Int. J. Lepr;65(2):271-302, Jun. 1997. .
Descritores:Hanseníase/clas
Hanseníase/diag
Hanseníase/epidemiol
Localização:BR191.1


  2 / 1850 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:27310
Autor:Cunha, Maria da Graça S; Schettini, Antonio P. M; Pedrosa, Valderiza L; Cruz, Rossilene C. S; Sadahiro, Megumi.
Título:Regarding Brasil, et al. 's adverse effects in leprosy's WHO/MDT and paramedic's role in Leprosy Control Program.
Fonte:Int. J. Lepr;65(2):257-259, Jun. 1997. tab.
Descritores:Hanseníase/quimioter
Hanseníase/epidemiol
Hanseníase/prev
Organização Mundial da Saúde
Brasil/epidemiol
Localização:BR191.1


  3 / 1850 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:27307
Autor:Li, Huan-Ying; Hu, Lu-Fang; Huang, Wan-Biao; Liu, Guo-Cai; Yuan, Lian-Chao; Jin, Zheng; Li, Xiong; Li, Jin-Lan; Yang, Zhong-Min.
Título:Risk of relapse in leprosy after fixed-duration multidrug therapy.
Fonte:Int. J. Lepr;65(2):238-245, Jun. 1997. tab, mapas.
Resumo:Between 1986 and 1995, 8307 leprosy patients have completed fixed-duration multidrug therapy (FD-MDT) and were followed annually for possible relapse. The mean relapse rate for multibacillary (MB) leprosy is 0.15/1000 person-years (py) and for paucibacillary (PB) 0.55/1000 py. There is no difference in the relapse rates between patients with or without chemotherapy before FD-MDT. In MB patients, the five relapses occurred between 4 and 7 years; in PB patients, five relapses occurred at 4-5 years after FD-MDT. Six additional PB relapses self-reported 1-4 years after the 5-year surveillance period and were not included in the relapse rates. Most PB patients relapsed into MB due to wrong classification and insufficient therapy. For the known 62 irregular MB patients the cumulative relapse rate is 6.5%. (AU)^ien.
Descritores:Hanseníase/quimioter
Hanseníase/epidemiol
Hanseníase/prev
Quimioterapia Combinada
Limites:Humanos
Localização:BR191.1


  4 / 1850 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:27306
Autor:Li, Huan-Ying; Hu, Lu-Fang; Wu, Pei-Wei; Luo, Jiu-Si; Liu, Xue-Ming.
Título:Fixed-duration multidrug therapy in multibacillary leprosy.
Fonte:Int. J. Lepr;65(2):230-237, Jun. 1997. tab, mapas.
Resumo:Six-hundred-fifty-seven active multibacillary (MB) leprosy patients were put on fixed-duration multidrug therapy (FD-MDT) between 1985 and 1992 (190 had had no and 235 had had previous treatment with dapsone) and were followed for 5 years after therapy. Two relapses occurred during year 5 of surveillance and both had received dapsone prior to chemotherapy, giving an overall relapse rate of 0.08/100 person-years (py). Excluding the two relapses, 99.4% of the MB patients converted to smear negativity at year 6 after a regular course of FD-MDT. The relapse rate for 35 MB patients with an initial bacterial index (BI) of > 4 with 5 years of surveillance was 0.24/100 py. Reactions occurred more frequently during the first 6 months of MDT, decreasing gradually thereafter, and reaching 0 in year 4 of surveillance. The deformity rate at intake was 22.7% and only 1.8% of MB patients developed new deformities or an increased grade in deformity during therapy. (AU)^ien.
Descritores:Hanseníase/quimioter
Hanseníase/epidemiol
Hanseníase/prev
Quimioterapia Combinada
Limites:Humanos
Masculino
Feminino
Localização:BR191.1


  5 / 1850 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:27303
Autor:Ponnighaus, Jorg M; Lienhardt, Christian; Lucas, Sebastian; Fine, Paul E. M; Sterne, Jonathan A. C.
Título:Comparison of bacillary indexes in slit-skin smears, skin and nerve biopsies; a study from Malawi.
Fonte:Int. J. Lepr;65(2):211-216, Jun. 1997. tab, graf.
Resumo:Data analyzed in this paper were collected within the framework of the Lepra Evaluation Project, an epidemiological study of leprosy in Karonga District, northern Malawi. For 212 patients information on the number of skin lesions, slit-skin smear and skin biopsy results were available. Among 61 patients with a single lesion none were slit-skin-smear positive and two had bacilli detected in skin biopsies. In contrast, among 119 patients with four or more lesions 34 (28.6%) versus 59 (49.6%) had bacilli detectable in slit-skin smears or skin biopsies, respectively. In a further 47 patients skin biopsy results could be compared with split-nerve biopsy results. In 20 of 47 patients the bacterial indexes (BIs) were identical in skin and nerve biopsies, while in 26 of 47 patients the BIs were higher in nerve than in skin biopsies. This difference, which is consistent with several other studies in the literature, provides an insight into the pathogenesis of leprosy. (AU)^ien.
Descritores:Hanseníase/epidemiol
Hanseníase/microbiol
Mycobacterium leprae/isol
Mycobacterium leprae/patogen
Limites:Humanos
Masculino
Feminino
Localização:BR191.1


  6 / 1850 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:27302
Autor:Broek, Jacques van den; Chum, Hamza J; Swai, Ronald; O´Brien, Richard J.
Título:Association between leprosy and HIV infection Tanzania.
Fonte:Int. J. Lepr;65(2):203-210, Jun. 1997. tab, graf.
Resumo:SETTING: An epidemiological study of the interaction of leprosy and HIV infection in Tanzania. OBJECTIVE: To establish the prevalence of HIV infection among leprosy patients, and to measure the association of HIV and leprosy by comparing the HIV prevalence in leprosy patients and blood donors. DESIGN: Testing for HIV infection in consecutively diagnosed leprosy patients (new and relapsed after MDT) in all regions in Tanzania successively for a period of 3 to 6 months during 1991, 1992 and 1993. RESULTS: Out of the total estimated eligible leprosy patients, 697 patients (69%) entered the final analysis. The HIV prevalence among these leprosy patients was 12% (83/697) as compared to 6% (8960/ 158,971) in blood donors examined in Tanzania during the same period. There were no significant differences in HIV seroprevalence by age, sex, residence or type of disease. However, the adjusted odds ratio (OR) of the presence of a BCG scar was 1.9 [95% confidence interval (CI) 1.1-3.3] among HIV-positive leprosy cases compared to HIV-negative leprosy cases. Comparing leprosy cases with blood donors as controls, the logistic regression model, controlling for sex, age group and residence, showed the OR for HIV seropositivity among leprosy patients to be 2.5 (95% CI 2.0-3.2). This association existed in all strata, but was strongest in the 15-34-year age group. No difference of HIV status between multibacillary and paucibacillary leprosy could be shown to exist. The point estimate of the population attributable risk of HIV infection for leprosy was 7%. CONCLUSION: HIV infection is associated with leprosy and might reverse the epidemiological trend of the slow decline in case notification in Tanzania if HIV infection is increasing greatly. Previous BCG vaccination loses its protection against leprosy in the presence of HIV infection. A repeated study is recommended in order to validate these findings, whereby recording of the disability grading of the cases is necessary to adjust for delay in diagnosis. (AU)^ien.
Descritores:Hanseníase/compl
Hanseníase/epidemiol
Anticorpos Anti-HIV/anal
Infecções por HIV/compl
Infecções por HIV/epidemiol
Limites:Humanos
Masculino
Feminino
Adolescente
Adulto
Localização:BR191.1


  7 / 1850 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:27301
Autor:Roger, Michel; Levee, Geraldine; Chanteau, Suzanne; Gicquel, Brigitte; Schurr, Erwin.
Título:No evidence for linkage between leprosy susceptibility and the human natural resistance-associated macrophage protein 1 (NRAMP1) gene in French Polynesia.
Fonte:Int. J. Lepr;65(2):197-202, Jun. 1997. tab.
Resumo:In order to determine whether a human homolog (NRAMP1) to a murine candidate gene for resistance to mycobacteria influences susceptibility to human disease, we analyzed data from seven multicase leprosy families (84 individuals) from French Polynesia for linkage markers within the NRAMP1 gene and leprosy per se. Individual family members were typed at nine polymorphic loci within NRAMP1. In addition, three physically linked, polymorphic microsatellite markers-D2S104, D2S173 and D2S1471-were also typed. Linkage analyses were done using affected sibpair and LOD score methods employing different modes of inheritance with full and reduced penetrance. The results of this study strongly suggest that NRAMP1 is not linked to leprosy susceptibility in the French Polynesian families tested. (AU)^ien.
Descritores:Hanseníase/epidemiol
Hanseníase/genet
Proteínas de Transporte/genet
Proteínas de Membrana/genet
Limites:Humanos
Masculino
Feminino
Localização:BR191.1


  8 / 1850 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:27294
Autor:Anon.
Título:Current literature.
Fonte:Int. J. Lepr;65(1):116-154, Mar., 1997. .
Descritores:Hanseníase/diag
Hanseníase/epidemiol
Hanseníase/prev
Localização:BR191.1


  9 / 1850 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:27253
Autor:Anon.
Título:Controlando a hanseníase: um desafio para o SUS no Instituto Lauro de Souza Lima / ?
Fonte:In: São Paulo(Estado). Secretaria de Estado da Saúde. Coordenadoria de Controle de Doenças.Vigilância em Saúde: 20 anos SUS-SP^ipt. São Paulo, s.n, 2008. p.51-61ilus.
Descritores:Hanseníase/epidemiol
Hanseníase/prev
Hanseníase/terap
Localização:BR191.1, S63v


  10 / 1850 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Texto Completo-en
Id:27249
Autor:Anon.
Título:Thirty-third U. S.- Japan Tuberculosis and Leprosy Research Conference.
Fonte:Int. J. Lepr;66(3):430-439, Sept. 1998. .
Conferência:Apresentado em: Thirty-third U. S.- Japan Tuberculosis and Leprosy Research Conference, Osaka, 08-10 July 1998.
Descritores:Tuberculose/epidemiol
Tuberculose/fisiopatol
Hanseníase/epidemiol
Hanseníase/fisiopatol
Meio Eletrônico:http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1998/pdf/v66n3/v66n3tlrc.pdf - en.
Localização:BR191.1


  11 / 1850 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Texto Completo-en
Id:27223
Autor:Anon.
Título:Epidemiology.
Fonte:Int. J. Lepr;66(4):75A-89A, Dec. 1998. graf.
Conferência:Apresentado em: International Leprosy Congress, 15, Beijing, 07-12 Sept. 1998.
Descritores:Hanseníase/epidemiol
Hanseníase/fisiopatol
Meio Eletrônico:http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1998/pdf/v66n4/v66n4abs06.pdf - en.
Localização:BR191.1


  12 / 1850 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Texto Completo-en
Id:27221
Autor:Anon.
Título:Control & Eradication.
Fonte:Int. J. Lepr;66(4):37A-60A, Dec. 1998. .
Conferência:Apresentado em: International Leprosy Congress, 15, Beijing, 07-12 Sept. 1998.
Descritores:Hanseníase/epidemiol
Hanseníase/prev
Meio Eletrônico:http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1998/pdf/v66n4/v66n4abs04.pdf - en.
Localização:BR191.1


  13 / 1850 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Texto Completo-en
Id:27214
Autor:Fine, Paul E. M; Truman, Richard.
Título:Report of workshop on epidemiology/ transmission/ vaccines.
Fonte:Int. J. Lepr;66(4):596-597, Dec. 1998. .
Conferência:Apresentado em: International Leprosy Congress, 15, Beijing, 07-12 Sept. 1998.
Descritores:Hanseníase/epidemiol
Hanseníase/prev
Hanseníase/transm
Meio Eletrônico:http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1998/pdf/v66n4/v66n4repcur03.pdf - en.
Localização:BR191.1


  14 / 1850 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Texto Completo-en
Id:27190
Autor:Feenstra, P.
Título:Minutes of general meetings of ILA members.
Fonte:Int. J. Lepr;66(4):557-558, Dec. 1998. .
Conferência:Apresentado em: International Leprosy Congress, 15, Beijing, 07-12 Sept. 1998.
Descritores:Hanseníase/epidemiol
Hanseníase/prev
Meio Eletrônico:http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1998/pdf/v66n4/v66n4min02.pdf - en.
Localização:BR191.1


  15 / 1850 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Texto Completo-en
Id:27189
Autor:Anon.
Título:Presentation by Dr. Jean Pierre Schenkelaars, ILEP President.
Fonte:Int. J. Lepr;66(4):555-556, Dec. 1998. .
Conferência:Apresentado em: International Leprosy Congress, 15, Beijing, 07-12 Sept. 1998.
Descritores:Hanseníase/epidemiol
Hanseníase/prev
Meio Eletrônico:http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1998/pdf/v66n4/v66n4opecer05.pdf - en.
Localização:BR191.1


  16 / 1850 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Texto Completo-en
Id:27188
Autor:Anon.
Título:Presentation by Dr. S. K. Nordeen, Sr. advisor, World Health Organization Action Programme for the Elimination of Leprosy.
Fonte:Int. J. Lepr;66(4):554-555, Dec. 1998. .
Conferência:Apresentado em: International Leprosy Congress, 15, Beijing, 07-12 Sept. 1998.
Descritores:Hanseníase/epidemiol
Hanseníase/prev
Meio Eletrônico:http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1998/pdf/v66n4/v66n4opecer04.pdf - en.
Localização:BR191.1


  17 / 1850 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Texto Completo-en
Id:27187
Autor:Dakui, Yin.
Título:Achievements and prospects on leprosy prevention and control in China.
Fonte:Int. J. Lepr;66(4):546-553, Dec. 1998. .
Conferência:Apresentado em: International Leprosy Congress, 15, Beijing, 07-12 Sept. 1998.
Descritores:Hanseníase/epidemiol
Hanseníase/prev
China/epidemiol
Limites:Humanos
Masculino
Feminino
Meio Eletrônico:http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1998/pdf/v66n4/v66n4opecer03.pdf - en.
Localização:BR191.1


  18 / 1850 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Texto Completo-en
Id:27166
Autor:Andrade, Vera; Sabroza, Paulo Chagastelles; Albuquerque, Maria de Fatima Militao de; Motta, Celio de Paula.
Título:Monitoring the elimination of leprosy in Brazil.
Fonte:Int. J. Lepr;66(4):457-463, Dec. 1998. tab, graf.
Resumo:A decreasing trend in the prevalence rate of leprosy was reached in Brazil only after the introduction of the World Health Organization multidrug therapy (WHO/MDT) program in 1990. This paper analyzes leprosy morbidity indicators and the prevalence rate, and their utilization in monitoring the progress of leprosy elimination in Brazil. Since these indicators are modified by changes in health service procedures, comparing prevalence rates from different endemic countries or current prevalence rates with old ones from the same endemic region needs careful attention. The current official prevalence rate of 6.72/10,000 inhabitants in Brazil could be considered high when compared with rates from other countries, but it is important to remember that defaulters and patients being treated with old regimens are kept on the active registers in Brazil, while in most other endemic countries they are not. (AU)^ien.
Descritores:Hanseníase/epidemiol
Hanseníase/prev
Meio Eletrônico:http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1998/pdf/v66n4/v66n4a03.pdf - en.
Localização:BR191.1


  19 / 1850 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Texto Completo-en
Id:27165
Autor:Solomon, Samuel; Kurian, Nisha; Ramadas, Palani; Rao, Pamidipai Samuel Simon Sudar.
Título:Incidence of nerve damage in leprosy patients treated with MDT.
Fonte:Int. J. Lepr;66(4):451-456, Dec. 1998. tab.
Resumo:The incidence rates of sensory and motor impairments during and after multidrug therapy (MDT) are reported for a prospective cohort of patients who had no nerve damage at registration (N = 1621). Sensory and motor loss increased with age and both were high among multibacillary patients as compared with paucibacillary patients. The lateral popliteal (common peroneal) and posterior tibial nerves seem to be most affected for sensory loss; whereas the posterior tibial and ulnar nerves are mainly responsible for motor loss. No significant difference by gender was found. Implications for prevention of disability (POD) activities are discussed and suitable recommendations made. (AU)^ien.
Descritores:Hanseníase/quimioter
Hanseníase/epidemiol
Hanseníase/fisiopatol
Mycobacterium leprae/patogen
Limites:Humanos
Masculino
Feminino
Adolescente
Meio Eletrônico:http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1998/pdf/v66n4/v66n4a02.pdf - en.
Localização:BR191.1


  20 / 1850 HANSEN  
              first record previous record
seleciona
para imprimir
Texto Completo-en
Id:27147
Autor:Saidi, Kiumars Ghazi; Stanford, John L; Stanford, Cynthia A; Rook, Graham AW; Dowlati, Yahya; Rees, Richard JW.
Título:Vaccination and skin test studies on children living in villages with differing endemicity for leprosy and tuberculosis.
Fonte:Int J Lep;57(1):45-53, Mar. 1989. ^btab.
Resumo:The purpose of this study carried out in Iranian Azerbaijan was to determine the pattern of skin-test positivity to mycobacterial antigens in children living in the valley, and to assess the effect on this of a series of vaccines against mycobacterial disease. Set up in 1978, 1707 tuberculin-negative children without scars of previous BCG vaccination were vaccinated with BCG Glaxo alone (vaccine A) or with the addition of a suspension of killed Mycobacterium vaccae (vaccine B). One hundred children were vaccinated with BCG Glaxo plus a suspension of M. leprae (vaccine C). Eight to 10 years later about half of the children were found for follow up. At this time further children were skin tested, and the results obtained were related to whether or not they had scars of vaccination with BCG Pasteur (Teheran) given by the local health authorities. Between setting up the study and the first follow up, cases of leprosy or tuberculosis had occurred in some of the villages, although not among those we had vaccinated. Differences between the effects of the vaccines were only found in villages with cases of leprosy. In these villages positivity to leprosin A was significantly greater after vaccine B (49%) than after vaccine A (36%; p less than 0.04). The results for scrofulin and vaccine were the same after both vaccines, and significantly lower than in the villages without cases of leprosy. The general reduction in skin-test positivity in the villages with leprosy cases was mainly due to a loss of category 1 responders to group i, common mycobacterial, antigens. It was concluded that where casual contact with cases of leprosy occurs the combination of BCG with killed M. vaccae is likely to be a better vaccine for leprosy than is BCG alone. Although few children received the combination with M. leprae, the results obtained were not particularly promising^ien.
Descritores:Hanseníase/epidemiol
Hanseníase/imunol
Tuberculose/epidemiol
Tuberculose/imunol
Limites:Humanos
Masculino
Feminino
Criança
Meio Eletrônico:http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1989/pdf/v57n1/v57n1a07.pdf - en.



página 1 de 93 ir para página                         
   


Refinar a pesquisa
  Base de dados : HANSEN Formulário avançado   
Pesquisar por : Formulário livre   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6.1 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information